Clinical trial

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

NCT00087412

Study summary

ClinicalTrials.gov

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record erlotinib hydrochloride Normalized identity: erlotinib hydrochloride View linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention laboratory biomarker analysis Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-09-01

PhasePHASE2

Conditions

Adenocarcinoma of the Lungverified · MONDO: lung adenocarcinoma

Large Cell Lung Cancerverified · MONDO: lung large cell carcinoma

Recurrent Non-small Cell Lung Cancerunresolved

Squamous Cell Lung Cancerverified · MONDO: squamous cell lung carcinoma

Stage IIIB Non-small Cell Lung Cancerunresolved

Stage IV Non-small Cell Lung Cancerunresolved

Interventions

erlotinib hydrochlorideDRUG · verified · RxNorm: erlotinib hydrochloride

laboratory biomarker analysisOTHER

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

San AntonioTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00087412 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.